ANN ARBOR, Mich., March 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today commended the expansion of federal support designed to advance stem cell research. The Company is particularly pleased to note the willingness of the new Administration and Congress to consider possible legislative activity with respect to federal funding for specific lines of stem cell research. This significant new activity underscores the enormous potential of all stem cell therapeutics.
